Identification of the business model components of the Iranian pharmaceutical companies
AbstractBackground: Today, the skill of business model analysis has become one of the key sources of competitive advantage and the development of innovative ideas in many industries. The purpose of this article is to identify and describe the business model dimensions and components of pharmaceutical companies as one of the most important strategic industries in any country.Methods: In the first step, by studying theoretical literature, we obtained an early model of the dimensions and components of a business model. Then a qualitative method was used. We tried to find this primitive pattern with the requirements of pharmaceutical companies. In this regard, we conducted 19 in-depth interviews with managers and experts of eight human pharmaceutical companies. The qualitative data were analyzed using analogous content analysis.Results: The results indicated that the business model of pharmaceutical companies consists of four main dimensions including value proposition, value receivers and interactions, value architecture, and received value. The first dimension consists of eleven components or attributes. The second dimension consists of three components. The third dimension consists of three components, and the fourth one consists of two components.Conclusion: This research differentiated the business model of pharmaceutical companies in four main dimensions, so that the elements that make up each dimension are different from the elements in the business model of other industries.
(1) Osterwalder A, Pigneur Y. Business model generation: A handbook for visionaries, game changers, and challengers. Hoboken, NJ: John Wiley & Sons; 2010.
(2) Al-Debei MM, Fitzgerald G. The design and engineering of mobile data services: developing an ontology based on business model thinking [PhD Thesis]; London, UK: Brunel University; 2014. 2018.
(3) Wetherbe JC, Turban E, Leidner DE, McLean ER. Information technology for management: Transforming organizations in the digital economy. Hoboken, NJ: John Wiley & Sons; 2007.
(4) Lambert S. A conceptual framework for business model research [Online]. [cited 2008]; Available from: URL: http://aisel.aisnet.org/bled2008/24
(5) Chesbrough H. Business model innovation: Opportunities and barriers. Long Range Plann 2010; 43(2): 354-63.
(6) Schmid B, Stanoevska-Slabeva K, Tschammer V. Towards the E-society: E-commerce, e-business, and e-government. Berlin, Germany: Springer Science & Business Media; 2001.
(7) Alt R, Zimmermann HD. Preface: Introduction to special section-business models. Electron Mark 2001; 11(1): 3-9.
(8) Stahler P. Business models as a unit of analysis for strategizing. Proceedings of the International Workshop on Business Models; 2002 Oct. 4-5; Lausanne, Switzerland. 2002.
(9) Afuah A, Tucci CL. A model of the internet as creative destroyer. IEEE Trans Eng Manag 2003; 50(4): 395-402.
(10) White S. Pharma 2020: The vision-which path will you take?: Pharmaceutical practitioner. S Afr Pharm J 2007; 74(8): 40-1.
(11) Sabatier V, Mangematin V, Rousselle T. From recipe to dinner: Business model portfolios in the european biopharmaceutical industry. Long Range Plann 2010; 43(2): 431-47.
(12) Ku MS. Recent trends in specialty pharma business model. J Food Drug Anal 2015; 23(4): 595-608.
(13) Danaeifard H, Alvani M, Azar A. Quantitative research methodology in management: A comprehensive approach. Tehran, Iran: Safar Publications; 2004.
(14) Anderson CR, Zeithaml CP. Stage of the product life cycle, business strategy, and business performance. Acad Manage J 1984; 27(1): 5-24.
(15) Cohen D, Crabtree B. Qualitative research guidelines project [Online]. [cited 2006]; Available from: URL: http://www.qualres.org/HomeEval-3664.html
(16) Johnson RB. Examining the validity structure of qualitative research. Education 1997; 118(2): 282-92.
(17) Stemler S. An overview of content analysis. Practical Assessment, Research & Evaluation 2001; 7(17): 1-6.
(18) Krippendorff K. Content analysis: An introduction to its methodology. Thousand Oaks, CA: SAGE; 2004.
(19) Hedman J, Kalling T. The business model concept: Theoretical underpinnings and empirical illustrations. Eur J Inf Syst 2003; 12(1): 49-59.
(20) Hamel G. Leading the revolution. Brighton, MA: Harvard Business School Press; 2000.
(21) Osterwalder A, Pigneur Y, Tucci CL. Clarifying Business models: Origins, present, and future of the concept. Communications of the Association for Information Systems 2005; 16: 1-25.
(22) Chesbrough H, Rosenbloom RS. The role of the business model in capturing value from innovation: Evidence from Xerox Corporation's technology spin-off companies. Industrial and Corporate Change 2002; 11(3): 529-55.
(23) Venkatraman N, Henderson JC. Real strategies for virtual organizing. Sloan Manage Rev 1998; 40(1): 33-48.
(24) Al-Debei MM, Avison D. Developing a unified framework of the business model concept. Eur J Inf Syst 2010; 19(3): 359-76.
(25) Osterwalder A. The business model ontology a proposition in a design science approach [PhD Thesis]. Lausanne, Switzerland: University of Lausanne; 2004.
(26) Gordijn J, Akkermans H, Van Vliet H. Business modelling is not process modelling. Proceedings of the 19th International Conference on Conceptual Modeling; 2000 Oct. 9-12; Salt Lake City, Utah.
(27) Petrovic O, Kittl C, Teksten RD. Developing Business Models for eBusiness [Online]. [cited 2001]; Available from: URL:
(28) JSB Intelligence. Strategic analysis of the pharma market, future revenue models and key players [Online]. [cited 2005]; Available from: URL: http://www.fgcasal.org/politicafarmaceutica/docs/JSB_Intelligence_resumen.PDF
(29) Capo F, Brunetta F, Boccardelli P. Innovative business models in the pharmaceutical industry: A case on exploiting value networks to stay competitive. Int J Eng Bus Manag 2014; 6: 1-11.
(30) Nasseri K. Selection of a suitable business model in the pharmacy company elixir (Public Joint Stock Company) [MSc Thesis]; Tehran, Iran: School of Management and Accounting, Allameh Tabataba'i University; 2018. [In Persian].